INO - Inovio Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
2.6950
-0.3050 (-10.17%)
As of 9:52AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close3.0000
Open2.7600
Bid2.7400 x 800
Ask2.7500 x 1800
Day's Range2.6200 - 2.8100
52 Week Range2.1500 - 6.3000
Volume377,298
Avg. Volume1,059,383
Market Cap264.201M
Beta (3Y Monthly)2.56
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • PR Newswire18 hours ago

    Inovio Sharpens Focus On HPV-Related Diseases And Fast-to-Market Product Candidates

    Company Cuts Selected Early-Stage R&D Programs, Burn-Rate by 25%, and Staff by 28% Management to Host Conference Call on July 17 at 8:00 AM EDT PLYMOUTH MEETING, Pa. , July 16, 2019 /PRNewswire/ -- Inovio ...

  • PR Newswire7 days ago

    Geneos Therapeutics Announces First Patient Dosed with its DNA-based, Neoantigen-Targeting Personalized Vaccine Technology

    PLYMOUTH MEETING, Pa., July 10, 2019 /PRNewswire/ -- Geneos Therapeutics, a clinical-stage biotech company, a spin-out of Inovio Pharmaceuticals (INO), announced today that the first cancer patient was dosed using the company's GT-EPIC Neoantigen-Targeting Personalized Vaccine Technology. In this first-in-human treatment – part of a clinical collaboration between Geneos and Washington University School of Medicine in St. Louis – a patient with Anaplastic Astrocytoma, a form of advanced brain cancer, is being treated on a Compassionate Use basis with the patient's own tumor-derived neoantigen vaccine.

  • PR Newswire9 days ago

    Inovio Completes Enrollment of VGX-3100 Phase 2 Trial for the Treatment of HPV-Related Vulvar Dysplasia (VIN)

    PLYMOUTH MEETING, Pa., July 8, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (INO) announced today that it has completed enrollment in its Phase 2 trial with VGX-3100 in patients with precancerous lesions of the vulva or vulvar intraepithelial neoplasia (VIN). VGX-3100 is an immunotherapy that targets human papillomavirus (HPV) 16 and 18 and is being studied for the treatment of HPV-related precancerous lesions and the HPV infection that causes these lesions. Inovio is already evaluating VGX-3100 in two Phase 3 registration trials (REVEAL 1 and REVEAL 2) to treat cervical dysplasia caused by HPV.

  • PR Newswire21 days ago

    Inovio Completes Enrollment of VGX-3100 Phase 3 Trial (REVEAL 1) for the Treatment of HPV-Related Cervical Pre-cancer

    PLYMOUTH MEETING, Pennsylvania, June 26, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (INO) today announced the completion of target enrollment of 198 participants for its pivotal Phase 3 registration trial ("REVEAL 1") of VGX-3100, a novel DNA-based immunotherapy being tested to treat cervical dysplasia caused by human papillomavirus (HPV). Left untreated, cervical dysplasia can progress to cervical cancer. If approved, VGX-3100 would be the first immunotherapy and non-surgical alternative for women with late-stage cervical dysplasia.

  • PR Newswirelast month

    Inovio Receives $8.14 Million Award to Support Further Development of its Commercial Skin Delivery Device

    PLYMOUTH MEETING, Pennsylvania, June 10, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (INO) announced today that the medical arm of the U.S. Defense Threat Reduction Agency (DTRA) will fund the further development of Inovio's new commercial intradermal delivery device. DTRA's Medical CBRN Defense Consortium will provide $8.14 million to support Inovio in developing a small, portable, battery-powered intradermal device branded as CELLECTRA® 3PSP to be used in the administration of Inovio's vaccines and therapies which include DTRA developed products.

  • PR Newswire2 months ago

    Inovio First to Advance Lassa Fever Candidate Vaccine Into a Clinical Trial

    PLYMOUTH MEETING, Pa. and OSLO, Norway, May 21, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (INO), together with CEPI, today announced it has dosed subjects in a Phase 1, first-in-human clinical trial to evaluate INO-4500, its DNA candidate vaccine to prevent infection from the Lassa virus. Inovio plans to enroll approximately 60 volunteers in this placebo controlled, blinded, dose escalation study evaluating INO-4500 for safety, tolerability and immune responses. This Inovio trial represents the first Lassa candidate vaccine to enter the clinic.

  • PR Newswire2 months ago

    Inovio and QIAGEN Establish Collaboration to Develop Diagnostic Test for VGX-3100, Inovio's Novel Immunotherapy Targeting Advanced Cervical Pre-Cancer

    Frankfurt Prime Standard: QIA) today announced a collaboration to co-develop a diagnostic test to identify patients most likely to respond to VGX-3100, Inovio's immunotherapy to treat advanced cervical dysplasia associated with the human papillomavirus virus (HPV). This precision medicine partnership focuses on Inovio's VGX-3100, a late-stage product candidate currently in two pivotal Phase 3 clinical trials (REVEAL 1 and 2) with potential to become the first treatment for HPV infection of the cervix and the first non-surgical treatment for precancerous cervical lesions associated with the virus.

  • PR Newswire2 months ago

    Inovio and Plumbline Life Sciences Establish Animal Health Collaboration to Develop A Novel Vaccine Against Deadly African Swine Fever Virus

    PLYMOUTH MEETING, Pa. and SEOUL, South Korea, May 15, 2019 /PRNewswire/ -- Inovio Pharmaceuticals Inc. (INO) and Plumbline Life Sciences (XKRX:222670) today announced a collaboration to co-develop a novel animal health vaccine for African swine fever (ASF) virus. The vaccine will be developed using Inovio's SynCon® technology and delivered using CELLECTRA® efficacy-enabling devices. Plumbline, based in South Korea, will fund all development and commercialization of the ASF vaccine.

  • PR Newswire2 months ago

    Inovio Pharmaceuticals Reports 2019 First Quarter Financial Results

    PLYMOUTH MEETING, Pa. , May 9, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO), an innovative biotechnology company focused on the discovery, development and commercialization of its synthetic ...

  • PR Newswire2 months ago

    Inovio Receives European Medicines Agency Certification For Quality and Non-Clinical Data for Its Phase 3 Product, VGX-3100

    PLYMOUTH MEETING, Pa. , May 6, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced that its lead Phase 3 product candidate, VGX-3100, has been granted an Advanced Therapy Medicinal ...

  • PR Newswire3 months ago

    Inovio Pharmaceuticals to Report First Quarter 2019 Financial Results on May 9, 2019

    PLYMOUTH MEETING, Pa., May 1, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (INO) announced today that first quarter 2019 financial results will be released after the market close on May 9, 2019. Following the release, the Company will host a conference call and live webcast at 4:30 p.m. ET, to provide a general business update and financial results for the first quarter 2019. Inovio is a late-stage biotechnology company focused on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines that transform the treatment and prevention of cancer and infectious disease. Inovio's proprietary technology platform applies antigen sequencing and DNA delivery to activate potent immune responses to targeted diseases. The technology functions exclusively in vivo, and has been demonstrated to consistently activate robust and fully functional T cell and antibody responses against targeted cancers and pathogens.

  • PR Newswire3 months ago

    Inovio Publishes Cancer Killing Data of Its Transformative DNA-encoded Bi-specific T Cell Engagers (dBiTEs™) in a Peer-reviewed Journal

    PLYMOUTH MEETING, Pa., April 18, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (INO) announced today the company's novel DNA-encoded Bi-specific T Cell Engagers (dBiTEs) generated potent anti-tumor activities and cleared established tumors in preclinical studies. Inovio's dBiTE results were published in a JCI Insight article entitled, "DNA-encoded bi-specific T cell engagers and antibodies present long-term antitumor activity," by Inovio and its collaborators at The Wistar Institute. JCI Insight is a peer-reviewed journal published by the American Society for Clinical Investigation dedicated to well-executed preclinical and clinical research studies.

  • PR Newswire3 months ago

    Inovio's Phase 3 HPV Immunotherapy Selected As "Best Therapeutic Vaccine" at World Vaccine Congress

    PLYMOUTH MEETING, Pa., April 17, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (INO) announced today that VGX-3100, its Phase 3 immunotherapy to treat cervical dysplasia, was recognized as "Best Therapeutic Vaccine" at the World Vaccine Congress held this week in Washington, D.C. The Vaccine Industry Excellence (ViE) Awards honor outstanding vaccine and immunotherapy advancements and achievements across the worldwide industry as judged by a panel of global biotech industry stakeholders. Dr. J. Joseph Kim, President and CEO, said, "We greatly appreciate the World Vaccine Congress' recognition of Inovio's breakthrough immunotherapy VGX-3100 that could offer the first non-surgical treatment to patients who are suffering from HPV-related pre-cancers that often progress to cancer.

  • PR Newswire3 months ago

    Inovio Achieves Third Cancer Indication Milestone for MEDI0457 Phase 2 Development

    PLYMOUTH MEETING, Pa. , April 8, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today that it achieved a third indication milestone from AstraZeneca resulting from dosing a patient ...

  • PR Newswire3 months ago

    Inovio's Novel HPV Therapy INO-3106 Demonstrates Clinical Efficacy Against Rare Respiratory Tract Tumors in Pilot Clinical Study

    PLYMOUTH MEETING, Pennsylvania, April 3, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (INO) today announced its novel therapy INO-3106 against the human papilloma virus type 6 (HPV 6) demonstrated clinical efficacy in a study of two patients with recurrent respiratory papillomatosis (RRP). RRP is an HPV-associated disease that can cause noncancerous tumor growths leading to life-threatening airway obstructions, and occasionally progresses to cancer. RRP is primarily caused by two strains of HPV, HPV 6 and 11, which also predominantly cause genital warts.

  • PR Newswire3 months ago

    Inovio Presents Cancer Killing Data of Its Transformative DNA-Encoded Bi-specific T Cell Engagers (dBiTEs) at AACR

    PLYMOUTH MEETING, Pennsylvania, April 2, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (INO) announced today the company's novel DNA-Encoded Bi-specific T Cell Engagers (dBiTEs™) generated potent anti-tumor activities in a preclinical study. For this study, Inovio, with its collaborators at The Wistar Institute, developed a novel dBiTE targeting the HER2 molecule which was tested in therapeutic models for the treatment of ovarian and breast cancers. Importantly, just a single dose of Inovio's HER2 dBiTE resulted in high levels of corresponding BiTE in mice for four months, far exceeding what is typically displayed with conventional BiTE's short half-life of only a few hours.